ES2705027T3 - Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados - Google Patents

Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados Download PDF

Info

Publication number
ES2705027T3
ES2705027T3 ES11818848T ES11818848T ES2705027T3 ES 2705027 T3 ES2705027 T3 ES 2705027T3 ES 11818848 T ES11818848 T ES 11818848T ES 11818848 T ES11818848 T ES 11818848T ES 2705027 T3 ES2705027 T3 ES 2705027T3
Authority
ES
Spain
Prior art keywords
compound
disease
mammal
administration
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11818848T
Other languages
English (en)
Spanish (es)
Inventor
Varghese John
Dale E Bredesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Buck Institute For Age Res
Buck Institute for Research on Aging
Original Assignee
Buck Institute For Age Res
Buck Institute for Research on Aging
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Buck Institute For Age Res, Buck Institute for Research on Aging filed Critical Buck Institute For Age Res
Application granted granted Critical
Publication of ES2705027T3 publication Critical patent/ES2705027T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES11818848T 2010-08-19 2011-08-19 Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados Active ES2705027T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40190710P 2010-08-19 2010-08-19
PCT/US2011/048472 WO2012024616A1 (en) 2010-08-19 2011-08-19 Methods of treating miild cognitive impairment (mci) and related discorders

Publications (1)

Publication Number Publication Date
ES2705027T3 true ES2705027T3 (es) 2019-03-21

Family

ID=45605447

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11818848T Active ES2705027T3 (es) 2010-08-19 2011-08-19 Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados

Country Status (10)

Country Link
US (1) US10449177B2 (enExample)
EP (1) EP2605655B1 (enExample)
JP (2) JP6250394B2 (enExample)
AU (1) AU2011291506B2 (enExample)
BR (1) BR112013003847A8 (enExample)
CA (1) CA2808630A1 (enExample)
DK (1) DK2605655T3 (enExample)
ES (1) ES2705027T3 (enExample)
MX (1) MX353096B (enExample)
WO (1) WO2012024616A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX353096B (es) 2010-08-19 2017-12-19 Buck Institute For Age Res Star Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
US20150209306A1 (en) 2012-08-07 2015-07-30 Buck Institute For Research On Aging Multi-component formulation for improving neurological function
EP3653609B1 (en) 2013-02-12 2024-04-03 Buck Institute for Research on Aging Hydantoins that modulate bace-mediated app processing
WO2014152207A1 (en) 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
US9993472B2 (en) 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
ES2960625T3 (es) 2014-03-21 2024-03-05 Alzheon Inc Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+
AU2016220049C1 (en) 2015-02-18 2021-02-25 Buck Institute For Research On Aging Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
JP2018516901A (ja) * 2015-05-18 2018-06-28 シナプテック・ディヴェロップメント・エルエルシーＳｙｎａｐｔｅｃ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｌｃ アミロイドβのガランタミンクリアランス
EP3347002B1 (en) 2015-09-10 2023-06-07 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population
US10441573B2 (en) 2015-12-09 2019-10-15 Brandeis University DBH inhibitors for treating memory loss
US20180250249A1 (en) * 2016-02-02 2018-09-06 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular population
AU2017264931B2 (en) 2016-05-12 2021-02-04 Buck Institute For Research On Aging Compounds to promote normal processing of APP
JP7790686B2 (ja) 2017-01-03 2025-12-23 バイオアトラ インコーポレイテッド 老化細胞の処置のためのタンパク質療法
MX2021000395A (es) 2018-07-11 2021-05-12 Rubedo Life Sciences Inc Composiciones senolíticas y usos de las mismas.
CN110232679A (zh) * 2019-05-24 2019-09-13 潘丹 一种阿尔茨海默症遗传生物标志物确定方法及系统
JP7618230B2 (ja) 2019-07-25 2025-01-21 学校法人東京理科大学 精神・神経系の疾患又は症状を治療し、予防し又は改善する剤

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS5936675A (ja) 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
JPH06507782A (ja) 1990-06-15 1994-09-08 サイオス　ノバ　インコーポレイテッド アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物
AU652997B2 (en) 1991-01-21 1994-09-15 Elan Pharmaceuticals, Inc. Test and model for alzheimer's disease
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5206264A (en) 1991-11-04 1993-04-27 Cypros Pharmaceutical Corporation Use of disulfiram to prevent cardiovascular damage
DE69233109T2 (de) 1992-01-07 2004-05-19 Elan Pharmaceuticals, Inc., San Francisco Transgene tiermodelle fur alzheimer-krankheit
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
AU702293B2 (en) 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
AU5002399A (en) 1998-07-17 2000-02-07 National Broach And Machine Company Full form roll finishing technique
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
ES2318902T3 (es) 1998-09-24 2009-05-01 PHARMACIA &amp; UPJOHN COMPANY LLC Secretasa en la enfermedad del alzheimer.
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US20040092511A1 (en) 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
US20070059367A1 (en) 2000-06-06 2007-03-15 Cherukuri S R Drug Delivery System and Associated Methods
US20020115727A1 (en) 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
US20020107244A1 (en) 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
JP4288263B2 (ja) 2002-10-25 2009-07-01 コレジウム ファーマシューティカル， インク． ｐ−ヒドロキシ−ミルナシプランの立体異性体およびその使用方法
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
FR2846559B1 (fr) 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
CA2557541C (en) 2004-02-26 2014-12-16 Aska Pharmaceutical Co., Ltd. Pyrimidine derivatives
US7794403B2 (en) 2004-04-21 2010-09-14 Mear Holding B.V. System for measuring pulsatile vascular resistance
US8470846B2 (en) * 2004-04-30 2013-06-25 National University Corporation Chiba University Remedy for psychoneurotic diseases
US8193250B2 (en) * 2004-10-22 2012-06-05 Mount Sinai School Of Medicine Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system
JP2008524332A (ja) 2004-12-20 2008-07-10 コレジウム ファーマシューティカル， インク． 睡眠傷害のための医薬組成物
DE602005019210D1 (de) 2004-12-23 2010-03-18 Xenoport Inc Von serinaminosäure abgeleitete prodrugs von propofol, zusammensetzungen, anwendungen und kristalline formen davon
US20090156581A1 (en) 2005-04-15 2009-06-18 Board Of Trustrees Of Michigan State University Aminergic pharmaceutical compositions and methods
GB0515090D0 (en) 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1993542A1 (en) 2006-03-01 2008-11-26 Galderma Research & Development, S.N.C. Method of treating inflammatory skin diseases using tropisetron, and pharmaceutical compositions thereof
SG173409A1 (en) 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
WO2008074896A1 (en) 2006-12-21 2008-06-26 Prendergast Patrick T Compositions and methods for treatment of chronic neurological disorders
CN101742991A (zh) 2007-05-03 2010-06-16 杰克·L·阿比瑟 和厚朴酚类似物及其在治疗癌症中的用途
US20090163451A1 (en) 2007-11-16 2009-06-25 Frank Porreca Methods for treating visceral pain
CL2007003877A1 (es) 2007-12-28 2008-06-27 Univ De Concepcion Lab Androma Composicion farmaceutica que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina; y su uso para el tratamiento de la dependencia de alcohol y cocaina.
US20110118189A1 (en) 2008-04-28 2011-05-19 Farr Stephen J Novel formulations for treatment of migraine
KR101653707B1 (ko) 2008-05-29 2016-09-02 알바니 몰레큘라 리써치, 인크. 5-ｈｔ3 수용체 조절제, 이의 제조 방법, 및 그의 용도
US8604087B2 (en) 2008-09-25 2013-12-10 Bioland Ltd. Composition for treating or preventing amyloid-related diseases comprising 4-O-methylhonokiol
BRPI0914080A2 (pt) 2008-10-08 2015-10-27 Bioplus Life Sciences Pvt Ltda "sistema de liberação de dosagem controlada, método de administração e processo de preparação do mesmo"
US20100099701A1 (en) 2008-10-20 2010-04-22 Auspex Pharmaceuticals, Inc. Isoquinolinone modulators of 5-ht3 receptors
CN101444508B (zh) 2008-12-29 2010-10-27 海南瑞基药物研究有限公司 一种注射用托烷司琼制剂及其制备方法
US9017718B2 (en) 2009-05-21 2015-04-28 Bionex Pharmaceuticals Llc Dual and single layer dosage forms
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US9790109B2 (en) * 2010-04-30 2017-10-17 General Electric Company Method for sanitizing an electrodeionization device
MX353096B (es) 2010-08-19 2017-12-19 Buck Institute For Age Res Star Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
KR101368587B1 (ko) 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US20150030683A1 (en) 2012-02-18 2015-01-29 Buck Institute For Research On Aging Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions

Also Published As

Publication number Publication date
JP6250394B2 (ja) 2017-12-20
US10449177B2 (en) 2019-10-22
BR112013003847A8 (pt) 2017-12-26
EP2605655B1 (en) 2018-10-24
EP2605655A1 (en) 2013-06-26
BR112013003847A2 (pt) 2016-05-31
AU2011291506A1 (en) 2013-03-14
CA2808630A1 (en) 2012-02-23
DK2605655T3 (en) 2019-02-04
JP2016193944A (ja) 2016-11-17
MX353096B (es) 2017-12-19
AU2011291506B2 (en) 2016-07-28
EP2605655A4 (en) 2014-01-08
MX2013001917A (es) 2013-10-25
US20120071468A1 (en) 2012-03-22
JP2013534256A (ja) 2013-09-02
WO2012024616A1 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
JP6250394B2 (ja) 軽度の認知障害（ｍｃｉ）および関連障害の処置方法
Paris et al. Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier
US10835546B2 (en) App specific BACE inhibitors (ASBIs) and uses thereof
JP5303458B2 (ja) β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法
ES2769578T3 (es) Hidantoínas que modulan el procesamiento de APP mediado por BACE
US20220054454A1 (en) Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions
US20190192503A1 (en) Novel methods of treating a neurodegenerative disease in a mammal in need thereof
US20090192199A1 (en) Pharmacological modulation of positive ampa receptor modulator effects on neurotrophin expression
WO2013123426A1 (en) Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer&#39;s conditions
US20170273996A1 (en) Dosing Regimens for Treating And/Or Preventing Cerebral Amyloidoses
US20130102538A1 (en) Method of treating alzheimer&#39;s disease using pharmacological chaperones to increase presenilin function and gamma-secretase activity
WO2025095099A1 (ja) 前頭側頭葉変性症治療剤及び治療用組成物